207 related articles for article (PubMed ID: 15947852)
1. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
[TBL] [Abstract][Full Text] [Related]
2. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
[TBL] [Abstract][Full Text] [Related]
3. Renal hypersensitivity vasculitis associated with dapsone.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Rabel-Filho OC; Martini-Filho D; Fontes CJ
Am J Kidney Dis; 2005 Oct; 46(4):e51-3. PubMed ID: 16183407
[TBL] [Abstract][Full Text] [Related]
4. Validation study of HLA-B*13:01 as a biomarker of dapsone hypersensitivity syndrome in leprosy patients in Indonesia.
Krismawati H; Irwanto A; Pongtiku A; Irwan ID; Maladan Y; Sitanggang YA; Wahyuni T; Tanjung R; Sun Y; Liu H; Zhang F; Oktavian A; Liu J
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008746. PubMed ID: 33064728
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
6. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
7. Mortality due to dapsone hypersensitivity syndrome complicating multi-drug therapy for leprosy in Nepal.
Pandey B; Shrestha K; Lewis J; Hawksworth RA; Walker SL
Trop Doct; 2007 Jul; 37(3):162-3. PubMed ID: 17716505
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
Lim JT; Tan T
Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
[TBL] [Abstract][Full Text] [Related]
9. Haematological and biochemical alterations in leprosy patients already treated with dapsone and MDT.
Queiroz RH; Melchior Júnior E; de Souza AM; Gouveia E; Barbosa JC; de Carvalho D
Pharm Acta Helv; 1997 Sep; 72(4):209-13. PubMed ID: 9372643
[TBL] [Abstract][Full Text] [Related]
10. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
11. Clinical trial for uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): adverse effects approach.
Cruz RCDS; Bührer-Sékula S; Penna GO; Moraes MEA; Gonçalves HS; Stefani MMA; Penna MLF; Pontes MAA; Talhari S
An Bras Dermatol; 2018 Jun; 93(3):377-384. PubMed ID: 29924240
[TBL] [Abstract][Full Text] [Related]
12. Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan.
Sheen YS; Chu CY; Wang SH; Tsai TF
J Dermatolog Treat; 2009; 20(6):340-3. PubMed ID: 19954390
[TBL] [Abstract][Full Text] [Related]
13. Dapsone hypersensitivity syndrome in a lepromatous leprosy patient--A Case Report.
Gavilanes MC; Palacio AL; Chellini PR; Nery JA; Rego JG
Lepr Rev; 2015 Jun; 86(2):186-90. PubMed ID: 26502691
[TBL] [Abstract][Full Text] [Related]
14. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Lockwood DN; Cunha Mda G
Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
[No Abstract] [Full Text] [Related]
15. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
16. Methemoglobinemia and dapsone levels in patients with leprosy.
Vieira JL; Riveira JG; Martins Ade N; Silva JP; Salgado CG
Braz J Infect Dis; 2010; 14(3):319-21. PubMed ID: 20835521
[TBL] [Abstract][Full Text] [Related]
17. [Immuno-allergic accidents with rifamipcin].
Flageul B; Wagner L; Cottenot F
Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
[TBL] [Abstract][Full Text] [Related]
18. New approaches to chemotherapy for leprosy.
Waters MF
Drugs; 1983 Dec; 26(6):465-7. PubMed ID: 6653446
[No Abstract] [Full Text] [Related]
19. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
Queiroz RH; Souza AM; Melchior E; Gouveia EG; Carvalho D
Lepr Rev; 1997 Sep; 68(3):212-7. PubMed ID: 9364821
[TBL] [Abstract][Full Text] [Related]
20. Biochemical and hematological side effects of clofazimine in leprosy patients.
Costa Queiroz RH; de Souza AM; Sampaio SV; Melchior E
Pharmacol Res; 2002 Aug; 46(2):191-4. PubMed ID: 12220960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
